Event Details

Verastem Inc at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nov 18, 2014 at 12:00 PM EST to Nov 21, 2014 at 11:59 PM EST
Title
Verastem Inc at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Date / Time
Nov 18, 2014 at 12:00 PM EST to Nov 21, 2014 at 11:59 PM EST

Title: A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
Abstract #: 296
Poster Board #: 076
Date: Thursday, November 20, 2014
Time: 9:00am GMT
Location: Exhibition Hall

Title: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy
Abstract #: 302
Poster Board #: 082
Date: Thursday, November 20, 2014
Time: 9:00am GMT
Location: Exhibition Hall

Title: PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer
Abstract #: 439
Poster Board #: 011
Date: Friday, November 21, 2014
Time: 9:00am GMT
Location: Exhibition Hall

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com